Clotamin, an over-the-counter multivitamin for people on blood thinners, will be carried by Navarro Discount Pharmacy and Walgreens.com.


Clotamin, Sunpeaks Ventures, Healthcare Distribution Specialists, multivitamin, blood thinners, Warfarin, anticoagulant, Navarro Discount Pharmacy, Walgreens.com, Mackie Barch










































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Clotamin lands distribution with Navarro, Walgreens.com

March 20th, 2012

SILVER SPRING, Md. – Clotamin, an over-the-counter multivitamin for people on blood thinners, will be carried by Navarro Discount Pharmacy and Walgreens.com.

Sunpeaks Ventures Inc. and its Healthcare Distribution Specialists subsidiary, which markets Clotamin, said Tuesday that the product will soon be available at Navarro's 31 drug stores across South Florida.

"We believe that Navarro is the leader of their regional pharmacy market and the inclusion of Clotamin to their shelves is another step toward our product reaching the entire South Florida territory," stated Mackie Barch, chief executive officer of Sunpeaks.

The company said Monday that Clotamin is available now on Walgreens.com, the website of the nation's largest drug chain, Walgreen Co.

"The addition of Walgreens.com is an important step for the distribution of Clotamin. Clotamin has a significant market to reach and this is just another step in the process," Barch commented. "We couldn't be more excited to have our product available on Walgreens.com."

Sunpeaks said Clotamin is the first specialized OTC multivitamin designed exclusively for use by patients on Warfarin or other anticoagulants. The company noted that Warfarin, a commonly used blood thinner, has a long list of adverse drug and food interactions.

Citing a report released by Global Industry Analysts, Sunpeaks said the global anticoagulants market is projected to top $11.2 billion by 2015, driven by an aging global population and rising incidence of cardiovascular diseases, cancer, and acute hip and knee complications, as well as emergence of therapeutics targeting new and previously targeted clotting factors.

Advertisement